BioLight Life Sciences Ltd. BOLT
TASE · Israel · Health Technology
ILA 290.10-6.30 (-2.13%)
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce it will be proceeding with a non-brokered private placement of up to 2,800,000 units ("Units") at a price of C$0.50 per Unit for aggregate gross proceeds of up to C$1,400,000 (the "Offering"). The Company expects BioLight Life Sciences Ltd., parent company of DiagnosTear, and Elcam Medical Ltd. to each participate for up to.
As most Gulf stock markets gain on the prospects of a U.S. rate cut, investor sentiment in the Middle East is buoyed by potential monetary easing and its implications for regional economies. Penny stocks, a term that may seem outdated, continue to capture interest due to their unique blend of affordability and growth potential. These smaller or newer companies can offer promising opportunities when supported by strong financials, making them an intriguing option for investors seeking...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.